Another FLT3 inhibitor, quizartinib, was granted priority review by the FDA based on the positive results of the phase III trial QuANTUM-First, which randomized newly diagnosed FLT3-ITD positive AML patients aged 18–75 to receive quizartinib 40 mg/day orally from days 8 to 21 vs. placebo in addition to induction with a cytarabine 100 mg/m2 continuous dose days 1 to 7 and daunorubicin 60 mg/m2 or idarubicin 12 mg/m2 days 1 to 3 [35]. This evidence concerns the gene FLT3 and acute myeloid leukemia.